Experimental AstraZeneca Drug Reduces COPD Flare-Ups in Late-Stage Trials

“A drug being developed by AstraZeneca significantly reduced flare-ups of chronic obstructive pulmonary disease in two late-stage trials, researchers ​reported on Tuesday at the medical meeting in Barcelona. Patients receiving Astra's tozorakimab during the year-long studies experienced about 29% to 34% fewer moderate-to-severe COPD exacerbations than those receiving a placebo, ‌the researchers reported. Overall rates […] The post Experimental AstraZeneca Drug Reduces COPD Flare-Ups in Late-Stage Trials appeared first on Human Progress.